Psychedelics for Psychotherapy - The Future is Now: The Biology Brief Ep 8

Explore the realm of psychedelic therapy in Episode 8 of "The Biology Brief." Join hosts Kiley Grant and Dr. Jim Cardelli as they analyze a groundbreaking paper on MDMA and PTSD, discussing flaws and the promising Phase 3 trial success. The episode covers the history of MDMA, clinical trials for PTSD, and potential FDA approval. Trace the evolution of psychedelic research from the 50s, dissect treatment protocols, and delve into the impact of various psychedelics. Learn about the formation of new neural connections with MDMA and Psilocybin, discuss adverse events, and contemplate the societal impact of creating drugs from natural products. Our company: https://www.oleo.live/ Buy Oligen here: https://oleocanthal.co/

Articles we read:

Article 1, Article 2, Article 3, Article 4 0:00 Introduction 0:59 First Paper by Mitchell et al to be discussed; MDMA and PTSD 1:21 Flaw in this paper? 2:47 Intro to MDMA 4:18 Post Traumatic Stress Disorder Overview 7:52 Clinical trials for PTSD treatment – MDMA 12:08 Phase 3 trial success predicts FDA approval in the near future. 12:45 Early studies in the 50s and 60s shut down in 1970 Nixon but growing since the 90s. 13:55 Clinical Treatment Protocol – who is in and who is not, cost? 19:44 Beyond MDMA. Other Psychedelics are being studied. 21:00 How do these drugs work? 21:45 MDMA action in the brain – new neural connections form 27:00 Psilocybin from Magic Mushrooms – New connections in the brain are formed 32:52 Adverse advents for these new treatments? 34:00 Can the hallucinogenic effects be separated from the improved response upon treatment? 36:08 Make new drugs from natural products – the impact on society and the health care system. 39:15 Wrap up